Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 2027

Earnings Call Insights: Lifecore Biomedical (LFCR) Q3 2025 Management View CEO Paul Josephs highlighted key achievements, including signing multiple agreements with new and existing customers, maintaining strong revenues aligned with guidance, and strengthening the cash balance through the sale of unused assets. Operational improvements.